

1 ORIGINAL RESEARCH

2 **Patient and practitioner views on a combined face-to-face and**
3 **digital intervention to support medication adherence in**
4 **hypertension: a qualitative study within primary care**

5

6

7 Miranda Van Emmenis¹, James Jamison¹, Aikaterini Kassavou¹, Wendy Hardeman²,
8 Felix Naughton², Charlotte A' Court¹, Stephen Sutton¹, Helen Eborall³

9 ¹ Behavioural Science Group, University of Cambridge, United Kingdom

10 ² School of Health Sciences, University of East Anglia, United Kingdom

11 ³ Usher Institute, University of Edinburgh, United Kingdom

12

13 Correspondence:

14 Miranda Van Emmenis

15 Behavioural Science Group, Primary Care Unit, East Forvie Building, Forvie Site,

16 Robinson Way, Cambridge, CB2 0SR

17 Tel 01223 330524

18 Email mv404@medschl.cam.ac.uk

19

20 Word count: 5992

21 **Abstract**

22 **Objectives:** To explore patients' and healthcare practitioners' views about non-
23 adherence to hypertension medication and potential content of a combined very brief
24 face-to-face discussion (VBI) and digital intervention (DI).

25 **Methods:** A qualitative study (N=31): interviews with patients with hypertension
26 (n=6) and healthcare practitioners (HCPs; n=11) and four focus groups with patients
27 with hypertension (n=14). Participants were recruited through general practices in
28 Eastern England and London. Topic guides explored reasons for medication non-
29 adherence and attitudes towards a potential intervention to support adherence.
30 Stimuli to facilitate discussion included example SMS messages and smartphone
31 app features, including mobile sensing. Analysis was informed methodologically by
32 the constant comparative approach and theoretically by Perceptions and
33 Practicalities Approach (PAPA).

34 **Results:** Participants' overarching explanations for non-adherence were non-
35 intentional (forgetting) and intentional (concerns about side-effects, reluctance to
36 medicate). These underpinned their views on intervention components: messages
37 that targeted forgetting medication or obtaining prescriptions were considered more
38 useful than messages providing information on consequences of non-adherence.
39 Tailoring the DI to the individuals' needs, regarding timing and number of messages,
40 was considered important for user engagement. Patients wanted control over the DI
41 and information about data use associated with any location sensing. While the DI
42 was considered limited in its potential to address intentional non-adherence, HCPs
43 saw the potential for a VBI in addressing this gap, if conducted in a non-judgemental
44 manner. Incorporating a VBI into routine primary care was considered feasible,

45 provided it complemented existing GP practice software and HCPs received
46 sufficient training.

47 **Conclusions:**

48 A combined VBI-DI can potentially address intentional and non-intentional reasons
49 for non-adherence to hypertension medication. For optimal engagement,
50 recommendations from this work include a VBI conducted in a non-judgmental
51 manner and focusing on non-intentional factors, followed by a DI that is easy-to-use,
52 highly tailored, and with provision of data privacy details about any sensing
53 technology used.

54

55 **Keywords:** medication adherence, qualitative research, high blood pressure, digital
56 intervention, healthcare professional, very brief face-to-face intervention

57

58

59

60

61

62

63

64

65

66 **Strengths and limitations of the study**

- 67 • To our knowledge, this is among the first qualitative studies to gather patient
68 views on the use of sensing technology such as Wi-Fi or GPS within a
69 smartphone app to support medication adherence.
- 70 • The study sought the views of a range of healthcare practitioners on
71 incorporating a very brief intervention for medication adherence into a primary
72 care consultation, a topic not previously explored in-depth.
- 73 • The use of stimulus materials provided detailed and focused responses for
74 specific intervention components such as feedback on adherence and content
75 of messages.
- 76 • While the sample size was small, the depth and focus of insights gained are
77 sufficiently useful in informing the development and refinement of intervention
78 components.

79

80 **Introduction**

81 Medication adherence, defined as the level to which an individual takes
82 medication as intended by their healthcare prescriber, is a worldwide public health
83 concern.[1] Non-adherence to blood pressure lowering medication is estimated at
84 41%, which is relatively high compared with many other medications.[2, 3] This is
85 associated with increased risk of cardiovascular disease related morbidity and
86 mortality.[4, 5] Given that high blood pressure is responsible for nearly 20% of
87 deaths worldwide, non-adherence to antihypertensive treatment is a global health
88 concern.[6]

89 Previous research into medication non-adherence has documented its
90 complexity and multifaceted nature.[7, 8] Two broad categories within this are (i)
91 non-intentional non-adherence, a passive process due to factors not directly within
92 an individual's control, such as memory or access difficulties,[8, 9] and (ii) intentional
93 non-adherence, a more deliberate action whereby an individual makes a conscious
94 decision not to take their medication due to their perceptions about or experiences
95 with their medication or condition.[9]

96 The multifaceted nature of non-adherence presents a challenge to those
97 developing interventions to support adherence; for example, determining which
98 factors to target, while balancing feasibility of delivery with likely effectiveness. Digital
99 interventions (DIs) such as SMS text messaging or smartphone applications (apps)
100 offer interactive, low cost and scalable methods of providing support to individuals for
101 whom medication adherence is a challenge. DIs are particularly suitable given the
102 increasing use of these by people across the age groups for day-to-day tasks, such
103 as apps for alarm clocks, calendars and shopping lists.[10] In addition, DIs can
104 potentially lower costs compared to traditional face-to-face approaches through
105 reducing or eliminating consultation time required with healthcare practitioners,
106 which may be particularly valuable at times when there is a high demand for
107 consultations e.g. during the current Covid pandemic. [11, 12]

108 Evidence for the effectiveness of DIs in improving medication adherence is
109 promising (e.g. see Thakkar et al [13]). In a recent systematic review of app-based
110 interventions, patients using a smartphone app to support medication adherence for
111 various health conditions were twice as likely to report taking their medications than
112 those receiving usual care.[14] Specific to hypertension, DIs such as SMS
113 messages, smartphone apps, email and Bluetooth blood pressure monitors have

114 been shown to improve medication adherence and lower both diastolic and systolic
115 blood pressure.[15, 16]

116 Incorporating sensing technology into smartphone apps potentially expands
117 the scope of DIs further. Passive smartphone sensors can collect user location data
118 via GPS or Wi-Fi to enable the delivery of real-time support [17], which is of
119 particular relevance given that non-intentional non-adherence is strongly influenced
120 by a person's physical environment.[18] Smartphone sensing technology has shown
121 success in DIs across the domain of health and well-being (e.g. see Cornet and
122 Holden for a review [19]) but user acceptability of such technology in a smartphone
123 app to support medication adherence is largely unknown.

124 While user acceptability is key to use of a DI, potential users first need to
125 install and engage with the DI for it to provide benefit. Primary care professionals,
126 such as practice nurses or community pharmacists are ideally placed for
127 encouraging uptake of DIs for medication adherence, for example during a
128 medication review or at the point of prescription collection. A DI used as an adjunct
129 to a face-to-face consultation might therefore be a promising approach to support
130 medication adherence. There is some evidence that DIs combined with tailored tele-
131 or web-based feedback from healthcare practitioners, improves adherence to long-
132 term medication [20] and antihypertensive medication.[21] However, evidence is
133 limited on how healthcare professionals can best promote the uptake of DIs for
134 medication adherence. The acceptability of combining a DI with a very brief face-to-
135 face intervention delivered by a healthcare professional to support medication
136 adherence has also not been widely explored.

137 This study aimed to explore patients' and healthcare practitioners' views on i)
138 non-adherence to hypertension medication and ii) a complex intervention designed
139 to support medication adherence. Initial ideas for the intervention consisted of a very
140 brief face-to-face discussion with a primary care provider, followed by ongoing
141 support via a DI (SMS messages or smartphone app). Feedback from participants
142 included preferred content of the intervention and factors likely to influence
143 engagement.

144

145 **Methods**

146 This study is reported in line with the consolidated criteria for reporting qualitative
147 research studies checklist (COREQ)[22], see supplementary file 1.

148 **Design**

149 We undertook a qualitative study using semi-structured interviews followed by focus
150 groups.

151 **Recruitment and sampling**

152 Patients were recruited for interviews from primary care practices based in the
153 East of England (n=3) and East London (n=1). Practices were identified with the help
154 of the Clinical Research Network, an organisation which supports the delivery of
155 research within NHS practices in England. Patients were eligible to participate if they
156 were: 1) prescribed at least one antihypertensive medication for at least the previous
157 three months 2) deemed non-adherent according to GP practice records, with a
158 blood pressure reading of over 140/90 mmHg and/or gaps in filling repeat
159 prescriptions in the previous three months and 3) used either SMS or smartphone

160 apps. The practice administrator at each site generated a list of prospective
161 participants that met criteria 1 and 2, which was screened by a GP or Practice
162 Nurse. Eligible patients received a study pack from their GP practice in the post
163 consisting of an invitation letter and participant information sheet. Posters
164 highlighting the study were also displayed in the GP practices. Patients interested in
165 taking part were invited to contact the researcher (MVE) via telephone or email; at
166 which point the researcher checked that all three eligibility criteria were met before
167 scheduling an interview.

168 A convenience sample of healthcare practitioners were recruited from the four
169 GP practices taking part in this study. Healthcare practitioners were eligible to be
170 interviewed if they were involved in the care of patients with hypertension e.g.
171 through medication reviews (conducted by a GP, Practice Nurse or Practice
172 Pharmacist) or blood pressure checks and/or health assessments (conducted by a
173 Healthcare Assistant). The researcher invited healthcare practitioners to participate
174 during the face-to-face study set-up meeting where they were given a study
175 information pack. The researcher contacted the healthcare practitioners one week
176 later to check willingness to participate and to schedule interviews for those who
177 were interested.

178 Recruitment for focus groups followed that of the patient interviews. To
179 address the low response from eligible patients, the eligibility criteria was widened to
180 include patients prescribed medication for type 2 diabetes, as research indicates
181 similar rates of medication non-adherence and barriers to adherence as for
182 hypertension.[23, 24] The eligibility criteria was also narrowed to ensure that
183 participants were familiar with using smartphone apps (i.e. SMS alone was not
184 sufficient). The decision to cease individual interviews and switch to focus groups

185 with patients was due to preliminary analysis from the interviews adding little new
186 information to findings from previous research, and our experience of the usefulness
187 of focus groups to gain feedback on the format, content and structure of DIs. [25–27]

188 **Data collection**

189 Patient interviews were conducted by one researcher (MVE) at patients’
190 home, workplace or local library. Healthcare practitioner interviews were conducted
191 at their place of work by the same researcher (MVE). Focus groups were conducted
192 at community centres local to the patients’ general practice and moderated by two
193 researchers (MVE and JJ).

194 Interviews and focus groups were guided by flexible topic guides [28]
195 developed by the research team, drawing on the Perceptions and Practicalities
196 Approach (PAPA) framework [18] and previous research experience in both the topic
197 area and intervention development. Topic guides were reviewed by Patient and
198 Public Involvement (PPI) representatives to ensure the questions were easy to
199 understand and appropriate for the study objectives. Broadly, interview topics
200 included: reasons for medication non-adherence, current practice of HCPs during
201 medication-related consultations, and views on a potential SMS text message or
202 smartphone app intervention that could support adherence. Example intervention
203 content included medication reminders, advice and support messages, and feedback
204 on adherence. See supplementary file 2 for the topic guides and example DI content.
205 HCPs were shown an example protocol for a very brief face-to-face discussion or
206 ‘VBI’ to generate discussion (see supplementary file 3). Components of the VBI
207 included: introducing the digital support to the patient and inputting basic patient
208 information via an online questionnaire to generate the tailored digital support.

209 Focus groups followed similar topic guides to the interviews, focusing on
210 attitudes towards smartphone apps in particular, including the acceptability of
211 sensing technology such as location sensing. To prompt discussion and gain
212 feedback, both interview and focus group participants viewed stimulus materials of
213 example intervention messages, including medication reminders, and smartphone
214 app features, including graphs and images (see Figure 1 for examples).

215 Written informed consent was taken in person by the researcher immediately
216 prior to the interviews and focus groups commencing. All patients received a £20
217 voucher for taking part. Interviews and focus groups were audio-recorded and
218 professionally transcribed verbatim. Interviews lasted on average 47 minutes and
219 focus groups 1 hour and 28 minutes.

220 **Data Analysis**

221 Analysis was informed methodologically by the constant comparative
222 approach[29] and theoretically by the Perceptions and Practicalities Approach
223 (PAPA), which incorporates and acknowledges the blurring of and distinction
224 between intentional and non-intentional non-adherence.[18] Interview transcripts
225 were read and re-read to aid familiarisation and identify preliminary themes; these
226 broad descriptive themes were formed into an initial coding framework related to
227 barriers and facilitators to medication adherence and a potential intervention. Each
228 transcript was then coded systematically (MVE) using NVivo qualitative data-
229 indexing software (version 12; QSR International) and the coding framework was
230 refined throughout the process. The process was repeated for focus group
231 transcripts; the coding framework was further expanded and refined, given the
232 additional topics explored in the focus groups. A sample of interview and focus group

233 transcripts were independently coded by a second researcher (JJ) to confirm and
234 strengthen the validity of findings. Meetings between the research team (MVE, JJ,
235 HE) facilitated data analysis including discussion of themes, sub-themes and the
236 interrelationships.

237 **Patient and public involvement**

238 All study materials (participant information sheet, invitation letter, study poster,
239 consent form, topic guides and stimulus materials) were reviewed by representatives
240 from the Cambridge University Hospitals Patient and Public Involvement (PPI) panel.
241 We made a number of changes to the study materials as a result of PPI input:
242 adjusted the language to make the documents more accessible and ensured
243 interview questions were sensitively worded and easy to understand from a patient
244 perspective. PPI representative Jennifer Bostock provided input throughout the study
245 and reviewed and commented on this manuscript.

246 **Ethical approval**

247 Ethical approval for this study was obtained from the West Midlands – Solihull
248 Research Ethics Committee, as part of NHS Health Research Authority approvals
249 (Reference: 18/WM/0050).

250

251 **Results**

252 Of the 126 eligible patients prescribed medication for hypertension who were
253 sent an invitation, six were interviewed. All 11 healthcare practitioners approached
254 by the researcher were deemed eligible and agreed to take part. Of the 218 patients
255 prescribed medication for hypertension and/or type 2 diabetes who were then sent

256 an invitation to a focus group, 14 participated (four focus groups with 3-5 patients per
 257 group). Recruitment of participants to focus groups continued until no new themes
 258 were emerging in relation to the specific topics covered.

259 Patient participant characteristics are reported in Table 1. Their mean age
 260 was 62.7 years (range 47 – 79 years), 60% identified as male and 85% as White
 261 British. Eighty percent of patients reported using both SMS and smartphone apps,
 262 with the remaining 20% using SMS text messages only. All patients self-reported
 263 having occasionally missed or skipped their medication in the previous 3 months.
 264 HCP participant characteristics are reported in Table 2; six Practice Nurses, two
 265 Healthcare Assistants, two Practice Pharmacists, one GP. Participants were
 266 recruited from four GP practices based in urban (n=3) and rural (n=1) locations. GP
 267 practice Index of Multiple Deprivation (IMD) scores, a measure of relative socio-
 268 economic status in England based on postcode, ranged from ‘least deprived’ (n=2),
 269 to ‘less deprived’ (n=1) and ‘more deprived’ (n=1), see Table 2.

270

271 **Table 1** Participant characteristics (patients)

272

Characteristics	(n)	%
Gender		
Female	8	40
Male	12	60
Age (years)		
41-50	2	10
51-60	4	20
61-70	11	55
71-80	3	15
Ethnicity		
Asian or Asian British – Indian	1	5
Asian or Asian British – Pakistani	1	5
Black or Black British – Caribbean	1	5
White British	17	85

		273	
Phone use			
SMS only	4	20	274
SMS and smartphone app	16	80	275
			Note: n=20
Data collection method			276
Semi-structured interview	6	30	
Focus group	14	70	
			277

278 **Table 2** Participant characteristics (healthcare practitioners) and GP practice
279 demographics

280

Characteristics	(n)	%	281
Healthcare practitioners			282
Job role			
General Practitioner	1	9	283
Healthcare Assistant	2	18	
Practice Nurse	6	55	284
Practice Pharmacist	2	18	
			285
Gender			286
Female	10	91	287
Male	1	9	
			288
Years practising			
≤10	5	46	289
11-20	2	18	
21-30	2	18	290
≥31	2	18	291
GP practices			292
GP practice location			
Urban	3	75	293
Rural	1	25	294
GP practice IMD quintile			295
First quintile (least deprived)	2	50	
Second quintile (less deprived)	1	25	296
Fourth quintile (more deprived)	1	25	297
			298

299 **Note:** Healthcare practitioner n=11, GP practice n=4, IMD = Index of Multiple Deprivation,
300 which ranks every small area in England from 1 ('most deprived area') to 32,844 ('least
301 deprived'). IMD scores of the 4 GP practices in this study: 9924, 25270, 26871, 30807.

302

303 To present the findings, we broadly categorise the key themes identified into
304 the following categories: reasons for non-adherence, recommendations for message
305 content, tailoring the digital intervention, acceptability of sensing technology, and
306 attitudes towards a VBI. We provide illustrative quotes below. See supplementary
307 file 4 for additional quotes from participants. For reference, 'digital intervention' (DI)
308 refers to both SMS text messages and smartphone app, as the same intervention
309 messages can be delivered using both formats.

310 ***Reasons for non-adherence***

311 Participants provided two key explanations of non-adherence to antihypertensive
312 medication. First, for *non-intentional* non-adherence, forgetting was the most
313 common reported reason and was mentioned in three ways: forgetting to take
314 medication, forgetting whether or not medication had been taken and forgetting to re-
315 order the prescription in time.

316 *Sometimes you can't remember whether you have taken them already. And*
317 *that can be problematic, so if someone asks you, you think, 'well, I don't know,*
318 *maybe I have, maybe that was yesterday.'* [P04, male, 40s]
319

320 Second, in terms of *intentional* non-adherence, the experience or anticipation of side
321 effects was a reason given for skipping, altering or delaying medication, as was the
322 general reluctance to be reliant on medication.

323 *I wish I could live without medication, I hate pumping my body with drugs.*
324 *Sometimes I wonder, 'what side effects am I gonna have with this? Is it really*
325 *benefitting me?'* [P06, female, 60s]

326 *A lot of patients [...have said], 'yes, the doctor has changed my medication,*
327 *but they make me go funny, so I'm just going to take half or I'll just crush that*
328 *and just take half instead of the two.'* [HCP 05, Healthcare Assistant, female]
329

330 These overarching explanations were apparent when participants discussed the
331 merits of a digital intervention to improve adherence, as presented in the following
332 sections. We begin with participants' views about a DI's messaging content, followed

333 by tailoring and then sensing technology; the final section considers the role of the
334 VBI component.

335 ***Recommendations for message content***

336 Simple reminder messages were perceived as useful for both taking medication and
337 re-ordering prescriptions.

338 *Even if I'm in a hurry, [when] I receive this reminder I [would] realise the*
339 *importance. I think if I keep getting messages that would be very effective and*
340 *definitely help me. Even if I'm tired and it would make me [...] I'd force myself*
341 *to get up and go and take the medication. [P06, female, 60s]*

342
343 *It would be useful, if you're running out of tablets, to have some way of*
344 *automatically reordering or a reminder to do that. So it's reminding you to take*
345 *your tablets, and also when you're running low. [P04, male, 40s]*

346
347 Information-giving messages were only perceived as helpful by participants if
348 providing advice when medication had been missed, for example the safest way to
349 'catch up' on a missed dose.

350 *There ought to be a button of 'I've forgotten them 'til now, which bits*
351 *should I take?' That could be useful. [FG3, male]*

352
353 While HCP-participants recommended messages about the benefits of medication or
354 the consequences of non-adherence, patient-participants considered these unhelpful
355 and unnecessary, particularly if lack of knowledge was not a barrier to adherence.

356 *I know what the risk is [from not taking my medication]. I don't feel that I want*
357 *it repeated, no. [P03, male, 60s]*

358 There was, however, some recognition that newly-diagnosed patients may find such
359 information motivating:

360 *If you're new to taking blood pressure tablets [information on consequences of*
361 *non-adherence] would be good. I mean, us experienced people who've taken*
362 *them for years most probably don't need reminding that if you don't take it,*
363 *something serious is gonna happen to you. [FG3, male]*

364

365 The idea of receiving feedback on one's adherence, generated from self-report via
366 SMS message or App, in a message of encouragement (e.g. 'Well done!') was
367 viewed as unnecessary. Participants were more receptive to schematic feedback in
368 the form of a graph, score or percentage.

369 *Some people might need that encouragement, but then again, it sounds a bit*
370 *patronising to some people, doesn't it [laughs]? [...] I think the percentage thing*
371 *would give people pride, you know, 'oh, I've reached 100% [of taking my*
372 *medication] this month, I feel really good about that'. Once a month I'd like to*
373 *know what my score was for the month. I think that would probably be enough*
374 *incentive for me personally. [P03, male, 60s]*

375
376 Regular smartphone users suggested that feedback in the form of a monthly
377 calendar highlighting 'missed medication' days, could be useful for spotting a pattern
378 and identifying the circumstances of those days that contributed to a missed dose.
379 Moreover, participants suggested the potential for this to facilitate discussion with a
380 healthcare professional too:

381 *A: I think [the app] would also be good to take, when you have a medication*
382 *review, to take to your GP so he or she can see what's going on as well.*

383 *B: Yeah, help fix it by doing something, yeah*
384 *[FG3, male (A, B)]*

385
386

387 ***Tailoring the digital intervention***

388 Participants commented how they would be more likely to use, and continue to use,
389 the DI if the messages were tailored to their preferences and their individual
390 medication regime, in terms of frequency and timing of doses:

391 *Some people are on medication once a day, twice a day, three, four. Could*
392 *the app be tailor-made for the individual? And remind us accordingly? [FG2,*
393 *female]*

394 *A: That's why [the intervention] should be tailor-made for the individual*
395 *patient. I think it's going to be critical really. Rather than a generic –*

396 *B: And have options, yeah.*

397 *A: Because if it's a generic app and it doesn't suit some people they won't use*
398 *it or they won't respond to it. [FG1, male (A,B)]*

399
400 Participants noted the importance of the DI including *all* their prescribed medications,
401 i.e. not just the hypertension ones.

402 *I think it would need to be somewhat of a select or deselect, you know, 'take*
403 *all' but you can un-tick the ones that you're not taking now. [FG4, female]*

404 *A: I would do it as all one. Even if you're doing it principally motivated by blood*
405 *pressure, in the sense it's, you're trying to remind us to take pills in general,*
406 *aren't you, so you have to somehow-*

407 *B: Yes, I think you want all of them there. [FG3, male (A), female (B)]*

408

409 To ensure that tailoring meets patients' preferences and medication regime, and the
410 changes over time, participants highlighted the importance of patients having control
411 over the DI's settings. For example, being able to change timings of reminders and
412 adding in short term medication.

413 *A: I think I'd like to put my own [medications] in. And then when you have a*
414 *"short course" [of medication] as we say, I'll add that in as well. I'd rather be in*
415 *charge of putting it in.*

416 *B: Especially as some you have to have on an empty stomach, don't you?*

417 *A: Yeah, so you could fiddle with your timings for that one. [FG2, female (A),*
418 *male (B)]*

419

420 *It's gotta be a dynamic thing. Medications change, dosages change, things*
421 *get stopped, times may change, so I probably would see as an app which*
422 *patients would be free to add and subtract. [HCP 02, GP, male]*

423

424 A 'snooze' function (similar to an alarm snooze) was well-received by participants,
425 provided users could set their own parameters, e.g., length of snooze duration and
426 maximum number of snoozes.

427 *It would be good for me 'cos I'm often not home when I'm supposed to take*
428 *them, so if you hit the 'snooze' for an hour or whatever you choose it to be,*
429 *[...]and it'll keep reminding me again and I'll take the tablets [when I'm home].*
430 *[FG1, male]*

431

432

433 A suggestion for tailoring by adding images of medications into the app raised more
434 problems than benefits; participants pointed out that “every time you get the
435 medication, the box changes” [FG1] and it was felt this would create confusion,
436 rather than help.

437

438 **Acceptability of sensing technology**

439 Participants were initially wary about the incorporation of sensing technology, such
440 as GPS or Wi-Fi to determine location, into an app. They raised concerns about
441 surveillance, typically referred to as “Big Brother” [FG1, FG3] watching them.

442 Participants were more likely to accept sensing technology if the perceived benefits
443 (such as tailoring medication reminders to their specific schedule and locations)
444 outweighed concerns about data privacy.

445 *It would make it impossible to forget ‘cos I’d just walk through the door and*
446 *take ‘em. That would be brilliant. [FG1, male]*
447

448 Participants requested information to address these concerns, including: who has
449 access to their data beyond the university (in particular, less trusted organisations
450 such as insurance or marketing companies), where data are stored, and what
451 happens in the event of hacking.

452 *A: Who are you gonna share this with? That’s all I’m worried about [...]*
453 *B: It could be pretty valuable information for insurance companies to put their*
454 *premiums up. [FG4, male (A), female (B)]*
455

456 *I think it’d be more reassuring to know it was a medical body behind it or a*
457 *university body behind it; it gives it some substance and credibility. [FG1,*
458 *male]*
459

460 Participants wanted to retain personal control over the sensing function, with the
461 ability to choose when the app tracks and records their location data as well as the

462 ability to opt in/out at any point.

463 *I think it would be a case of opt-in because I think some people would think it*
464 *an invasion of privacy. I mean, personally I think it's a good idea but, you see,*
465 *some people wouldn't like it. [FG4, female]*
466

467 Discussions about sensing technology prompted participants to suggest further ideas
468 for functions of an app. Participants in two focus groups suggested linking the
469 sensing technology with the smartphone calendar, to proactively detect periods
470 when away from home, triggering reminder messages to pack medication or re-order
471 prescriptions.

472 *The app ought to be able to detect [that] my calendar says, 'Away for the*
473 *weekend.'* So the app could say, "Ooh look, you're going away for the
474 *weekend"* it could send me a message or something on the Friday to make
475 *sure I pack them. That's almost what I want to be reminded of. [FG3, male]*
476

477 Participants emphasised the need for additional features to be optional, recognising
478 that over-complicating the DI risked disengagement from potential users.

479 *I suppose it's a case though of getting sufficient ability to customise it against*
480 *making it just too longwinded and complicated for people to be bothered.*
481 *[FG4, female]*

482 *I'm just trying to think of just the least steps possible for the patient, because*
483 *just adding more things is going to make them less likely to use these sorts of*
484 *things... It needs to just be easy for them. [HCP 01, Practice Pharmacist,*
485 *female]*
486

487 Above all, participants emphasised the importance of the DI being user-friendly for
488 the target group, many of whom may be less familiar with smartphones.

489 *The caveat I suppose might be that those that tend to have the chronic*
490 *diseases tend to be the older age group so they may not be so tech savvy.*
491 *We've got some patients who don't use mobile phones even now. [HCP 02,*
492 *GP, male]*
493

494

495 **Attitudes towards a very brief face-to-face intervention (VBI)**

496 Patient-participants' discussions about the DI functions largely focused on
497 addressing non-intentional non-adherence - mainly forgetting. On the whole, they
498 were sceptical about a DI's success in addressing intentional non-adherence:

499 *If they're not taking the tablets and they don't wanna take the tablets, why*
500 *would they sign up for the app? [FG1, male].*

501 HCP-participants suggested including messages encouraging users to contact their
502 healthcare provider if experiencing problems with their medication.

503 *That would be really useful in that if they're stopping it for any reason it needs to*
504 *come up with a message to say, "Please make an appointment with your GP.*
505 *There may be alternative medications available which would suit you and you*
506 *need to make an appointment to discuss that". [HCP 03, Practice Nurse, female]*
507

508 However, a more promising way of addressing intentional non-adherence was
509 highlighted in relation to the 5-minute VBI component prior to use of the DI. The VBI
510 was presented as a way for HCPs to signpost patients to the DI and discuss
511 medication taking behaviour. HCPs talked positively about how, if done in a non-
512 judgemental way and by an HCP with an established rapport with the patient, this
513 could foster open communication and a more constructive consultation.

514 *That's the important thing, when patients can relate to you and they can see*
515 *that you're actually not judging them, they do tend to then engage better.*
516 *[HCP 07, Practice Nurse, female]*

517 A key aspect of encouraging honest communication in the VBI would be
518 acknowledging that it is acceptable to have concerns about being prescribed
519 medication. HCPs recommended asking the patient to talk through these concerns
520 and, if needed, book a follow-up consultation with a prescribing practitioner about
521 changing medication.

522 *Have a discussion with them as to what's been happening, what the issues are,*
523 *how we can make it easier for them [...] 'Is there a problem with it? Are you*
524 *getting side-effects? Do you find it difficult to take?' And then we can explore*
525 *some of the issues. What is really important is to sift through what the issues*

526 *are. Our role in the face-to-face is actually we can explore some of these things*
527 *a bit easier. [HCP 06, Practice Nurse, female]*

528
529 All HCPs perceived the VBI element as feasible to deliver within primary care,
530 recommending incorporating it alongside a medication review or blood pressure
531 check. HCPs had two key provisos: training to help them deliver the VBI within the
532 tight timing of five minutes, and a “*user-friendly*” template that could be incorporated
533 in existing computer systems for inputting patient data to inform the subsequent DI.
534 HCPs also noted the need for sufficient training in using the DI itself, given their role
535 in encouraging its use in their patients following the VBI.

536 *I think that will be important, that whoever is talking about the app needs to*
537 *know how it works and how you use it... Because if somebody who is*
538 *recommending it doesn't know how to use it then you're not gonna buy into it.*
539 *[HCP 09, Practice Nurse, female]*

540

541

542

543

Discussion

544 **Summary of main findings**

545 Patients prescribed antihypertensive medication and the healthcare
546 practitioners that care for them, highlighted nonintentional (forgetting) and intentional
547 (side-effects, reluctance to medicate) reasons for their non-adherence. Participants
548 found a mobile digital intervention (DI) that provided simple medication reminders
549 and feedback messages acceptable. To facilitate engagement with the DI,
550 participants recommended it was tailored to the needs of the individual and their
551 medication regime as well as providing user control over the tailoring and other
552 optional functions. The use of sensing technology within a smartphone app was
553 acceptable to participants provided they received comprehensive information about
554 the associated use and confidentiality of their data.

555 While the DI was considered limited in its potential to address intentional non-
556 adherence, HCPs saw the potential for a brief face-to-face discussion (or 'VBI') with
557 patients in addressing this gap, when delivered alongside a DI. Incorporating a VBI
558 into a routine primary care was considered feasible, if it could be integrated into
559 existing practice software systems and if training were provided.

560 **Strengths and limitations of the study**

561 Drawing on relevant theory, [8, 9, 18] this study was conducted as
562 development work with a target patient group to inform aspects of an intervention as
563 part of a larger research programme.[30] Whilst previous research has investigated
564 the use of sensing technology and smartphone apps for health, [19] this study is
565 among the first to gather qualitative data on the acceptability of such technology (e.g.

566 Wi-Fi or GPS) in a smartphone app designed to support medication adherence (see
567 also Kassavou and colleagues [31]). Whilst advances in technology can provide
568 additional features to smartphone apps, it is important to assess the intended user
569 group's views of such technology before its implementation.[32]

570 We gained insights from a range of healthcare practitioners on the
571 acceptability and feasibility of incorporating a VBI for medication adherence into a
572 primary care consultation, a topic that has not been previously explored in-depth.
573 The recommendations arising from our findings can inform the development and
574 implementation of a medication adherence VBI in primary care. Developers should
575 consider the following: the importance of the practitioner-patient relationship when
576 discussing medications, exploration of patient-specific barriers to adherence,
577 templates embedded within existing GP practice systems, and sufficient training for
578 HCPs.

579 The use of stimulus materials generated discussion in the interviews and
580 focus groups, and provided focused responses for specific hypothetical intervention
581 components.

582 We acknowledge that this is a small-scale qualitative study, where 85% of the
583 patient sample were White British and 91% of the healthcare practitioner sample
584 were female. As such, the findings may be limited in their application to a patient and
585 healthcare professional population. However, the depth and focus of insights gained
586 provided rich data that were sufficiently useful in informing the development and
587 refinement of intervention components for the wider programme, and to similar
588 interventions.

589 We experienced challenges with recruiting patients through GP practices, particularly
590 those who were non-adherent to their medication, a group who may be less likely to
591 participate in a study of this nature. For future studies we would recommend
592 widening recruitment methods to include patients not tied to a specific sample of GP
593 practices, e.g. via social media channels or community groups. We acknowledge the
594 possibility that patients who are intentionally nonadherent to their medication may be
595 unwilling to download an adherence app or receive SMS support messages. In these
596 instances, alternative, more intensive intervention methods involving multiple BCT
597 components may be considered appropriate, such as motivational interviewing
598 delivered face-to-face and/or over the telephone.[33–35]

599

600 **Comparisons with existing literature**

601 The findings echo previous research that has identified the main reasons for
602 non-adherence to cardiovascular-related medication as forgetting and side-effects,
603 [24] [36] as well as the broad categorisation of reasons into intentional and non-
604 intentional.[37, 38] In our study, this distinction was particularly helpful when
605 considering which elements of an intervention were appropriate for targeting these
606 two broad categories.

607 Participants with lived experience of hypertension saw little value in
608 information-style messages (e.g. about the consequences of non-adherence) in
609 addressing intentional non-adherence. Rather, they suggested that such messages
610 may be most helpful for newly diagnosed patients. This follows previous qualitative
611 research in which mHealth interventions were deemed especially appropriate for
612 “newbies” [39] i.e. patients with less experience in managing a health condition

613 compared to those with established medication routines, for atrial fibrillation [40] and
614 type 2 diabetes. [39] Similar to previous studies [26], participants expressed
615 concerns about receiving too many messages, suggesting this would influence
616 (dis)engagement with the DI. Participants also emphasised the need for a DI to be
617 as simple and easy-to-use as possible, another common theme in usability studies
618 for medication adherence DIs, whereby difficulties with navigating a website, SMS or
619 smartphone app have presented barriers to usage.[41, 42] A related concern is the
620 potential burden that self-monitoring DIs place on the user, for example, asking
621 patients to self-report their medication taking behaviour within a set timeframe.[43,
622 44] Our findings support the need for usability testing with the DI target users, which
623 could include assessing any associated burdens or extra responsibilities placed on
624 the user.

625 Participants in this study saw the benefit that sensing technology could
626 provide but raised data privacy concerns about its use within a medication reminder
627 smartphone app, requesting comprehensive information and user control. Similar
628 concerns have been identified in previous research into location-sensing apps. For
629 individuals living with HIV, the acceptability of location-based self-monitoring
630 reminders was dependent on the purpose of the app and who would have access to
631 their data [45]. Similarly, young adults in Dennison [46] worried about the storage of
632 personal location data collected by health apps and wanted control over
633 personalising the app settings.

634 Despite the privacy concerns, participants in this study viewed a location-
635 sensing smartphone app more favourably if it was created by a university or charity
636 rather than a commercial company. This follows user feedback of other location-
637 based apps for smoking cessation, [47] medication adherence [31] and mental

638 health, [48] in which apps designed by universities or for research purposes were
639 deemed more trustworthy by participants. This reflects the discourse around the
640 ethics of mHealth, whereby third parties and insurance companies pose potential
641 threats to the safety of patients' health data collected by sensors or smartphone
642 apps.[43] These ethical considerations are of particular importance given the rise of
643 mHealth in the healthcare sphere.

644

645 **Recommendations for an intervention to support medication adherence**

646 The findings from this study have several implications for the development of
647 a DI to support medication adherence. To encourage engagement with an
648 intervention, it needs to be highly tailored to each individual. This includes: the timing
649 and content of reminder messages (to address non-intentional non-adherence) and
650 the content of support messages (for intentional non-adherence), where knowledge
651 and duration of health condition varies between individuals. Furthermore, a key
652 tailoring variable as recommended by HCP-participants was the individual patient's
653 specific barrier(s) to adherence. Tailoring data can be collected using various
654 methods, ideally before the start of the intervention for optimal impact. This could
655 include a short questionnaire, in person or by phone with a practitioner, within a
656 smartphone app, or via a set of SMS messages requiring responses.[26]

657 It was common for participants in this study to be taking multiple medications
658 per day, and most wanted this to be reflected in the medication reminders. This
659 requires a balance between providing appropriate adherence support without over-
660 complicating the DI or overburdening the user, resulting in reduced intervention
661 engagement.[49]

662 This study obtained novel insight from patients on the use of passive sensing
663 technology within a medication adherence smartphone app. To increase the
664 acceptability of sensing technology, future apps should explain the benefits that it
665 can provide to the user, such as tailored medication reminders based on real-time
666 location, or prompts to pack medication for upcoming holidays detected via calendar
667 syncing. The app must provide a flexible opt in/out option for the collection of
668 sensing data as well as information on how personal data will be used and stored
669 within the app. Lastly, users may be more accepting of a location-sensing app
670 created by a university or charity rather than a commercial company.,

671 Primary care was viewed as an appropriate setting for HCPs to introduce
672 patients to a DI and pair it with a brief behavioural face-to-face discussion, or 'VBI'.
673 More specifically, this could address intentional non-adherence by exploring the
674 specific barriers to medication adherence with patients. Using a non-judgemental
675 approach for this, would encourage patients' openness, which in turn would provide
676 more useful information for tailoring the DI and possibly making adjustments to the
677 all patient's regime as part of the usual care. This supports a body of literature on
678 shared decision-making [50] which has demonstrated an association between an
679 improved patient-professional partnership and medication adherence, for a variety of
680 conditions [51] and for hypertension specifically.[50, 52] Delivering a VBI requires
681 skill, in order to incorporate all elements and within the short timeframe.[53, 54] Our
682 findings indicate the importance of comprehensive training for healthcare
683 professionals which incorporate the principles of shared decision-making and the
684 skills to deliver the intervention in under five minutes, as well as proficiency in using
685 a DI. Lastly, the template for HCPs to complete the VBI and/or enter patients' details

686 into the DI should be user-friendly and embedded into existing GP practice software
687 systems.

688

689 **Conclusion**

690 Overall, patients and healthcare practitioners saw the benefit of receiving
691 medication reminders via SMS message or smartphone app. Intervention developers
692 should consider an intervention that is highly tailored to the user, straightforward to
693 use, and addresses data privacy concerns. The use of sensing technology in an
694 adherence support smartphone app was acceptable to patients, therefore future
695 research could investigate the feasibility of incorporating such technology into a
696 smartphone app for adherence. A routine primary care consultation was viewed as
697 an appropriate setting to introduce the DI to patients and discuss medication-taking
698 behaviour with patients, but the feasibility of delivering it as 'very brief' i.e. under five
699 minutes, should be explored further.

700

701 **Supplementary material**

702 S1 – COREQ checklist

703 S2 – Topic guides and sample of proposed intervention content

704 S3 – Example VBI protocol

705 S4 – Extra participant quotations

706

707 **Figure 1 (legend)**

708 Example digital intervention content to generate discussion in interviews and focus
709 groups; medication reminder notification, feedback on medication adherence levels
710 (weekly and monthly), SMS support message

711

712 **Acknowledgements**

713 This study was conducted on behalf of the Programme on Adherence to Medication
714 team (see [https://www.phpc.cam.ac.uk/pcu/research/research-projects-list/other-
715 projects/pam/](https://www.phpc.cam.ac.uk/pcu/research/research-projects-list/other-projects/pam/) for team members). We acknowledge and thank the following
716 individuals for contributing to the development of the topic guides and visual prompts
717 for this study: Jagmohan Chauhan and Sandra Servia, Department of Computer
718 Science and Technology, University of Cambridge; Debi Bhattacharya, School of
719 Pharmacy, University of East Anglia.

720 We thank the patients, healthcare practitioners, practice managers and
721 administrative staff at the 4 GP practices who took part in this study. We are grateful
722 to Patient and Public Involvement (PPI) representatives for reviewing the design and
723 ethics of this study. We thank PPI representative Jennifer Bostock for their input
724 across the whole study and for reviewing the manuscript. We acknowledge the
725 support of the National Institute for Health Research Clinical Research Network
726 (NIHR CRN).

727 **Author contributions**

728 All authors made substantial contributions to the conception and design of the study.
729 MVE conducted the interviews, co-facilitated the focus groups, conducted data
730 analysis and drafted the manuscript. JJ co-facilitated the focus groups, contributed to
731 data analysis and drafted the manuscript. HE provided supervision and guidance for

732 data collection, contributed to data analysis and drafted the manuscript. SS, FN, WH,
733 AK and CA critically revised the manuscript and provided intellectual input and
734 expert advice. All authors have read and approved this manuscript.

735 **Funding**

736 This article presents independent research funded by the National Institute for Health
737 Research (NIHR) under the Programme Grants for Applied Research programme
738 [RP-PG-0615-20013]. The views expressed in this publication are those of the
739 author(s) and not necessarily those of the NIHR or the Department of Health and
740 Social Care.

741 **Competing interests**

742 None declared.

743 **Ethics approval**

744 This study was approved by the West Midlands – Solihull Research Ethics
745 Committee, as part of NHS Health Research Authority approvals (Reference:
746 18/WM/0050).

747 **Data availability statement**

748 Data are available upon reasonable request from the corresponding author.

749 **Abbreviations:** COREQ, consolidated criteria for reporting qualitative research; DI,
750 digital intervention; GP, general practitioner; HCP, healthcare practitioner; IMD,
751 Index of Multiple Deprivation; NHS, National Health Service; NIHR CRN, National
752 Institute of Health Research Clinical Research Network; VBI, very brief intervention.

753

754

755

756

757 **References**

- 758 [1] Sabaté E, World Health Organization (eds). *Adherence to long-term therapies: evidence for*
759 *action*. Geneva: World Health Organization, 2003.
- 760 [2] Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis
761 of prevalence and clinical consequences. *Eur Heart J* 2013; 34: 2940–2948.
- 762 [3] Gupta Pankaj, Patel Prashanth, Štrauch Branislav, et al. Risk Factors for Nonadherence to
763 Antihypertensive Treatment. *Hypertension* 2017; 69: 1113–1120.
- 764 [4] Forouzanfar MH, Liu P, Roth GA, et al. Global Burden of Hypertension and Systolic Blood
765 Pressure of at Least 110 to 115 mm Hg, 1990-2015. *JAMA* 2017; 317: 165–182.
- 766 [5] Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. *Nat Rev Nephrol* 2020;
767 16: 223–237.
- 768 [6] Gakidou E, Afshin A, Abajobir AA, et al. Global, regional, and national comparative risk
769 assessment of 84 behavioural, environmental and occupational, and metabolic risks or
770 clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study
771 2016. *The Lancet* 2017; 390: 1345–1422.
- 772 [7] Brown MT, Bussell JK. Medication Adherence: WHO Cares? *Mayo Clin Proc* 2011; 86: 304–
773 314.
- 774 [8] Horne R, Weinman J, Barber N, et al. Concordance, adherence and compliance in medicine
775 taking.
- 776 [9] Clifford S, Barber N, Horne R. Understanding different beliefs held by adherers, unintentional
777 nonadherers, and intentional nonadherers: application of the Necessity-Concerns
778 Framework. *J Psychosom Res* 2008; 64: 41–46.
- 779 [10] Choudrie J, Pheeraphuttrangkoon S, Davari S. The Digital Divide and Older Adult Population
780 Adoption, Use and Diffusion of Mobile Phones: a Quantitative Study. *Inf Syst Front* 2020; 22:
781 673–695.
- 782 [11] Baird B, Charles A, Honeyman M, et al. Understanding pressures in general practice. 100.

- 783 [12] King R, Ryan T, Senek M, et al. The impact of COVID-19 on work, training and well-being
784 experiences of nursing associates in England: A cross-sectional survey. *Nurs Open*; n/a. DOI:
785 10.1002/nop2.928.
- 786 [13] Thakkar J, Kurup R, Laba T-L, et al. Mobile Telephone Text Messaging for Medication
787 Adherence in Chronic Disease: A Meta-analysis. *JAMA Intern Med* 2016; 176: 340–349.
- 788 [14] Armitage LC, Kassavou A, Sutton S. Do mobile device apps designed to support medication
789 adherence demonstrate efficacy? A systematic review of randomised controlled trials, with
790 meta-analysis. *BMJ Open* 2020; 10: e032045.
- 791 [15] McLean G, Band R, Saunderson K, et al. Digital interventions to promote self-management in
792 adults with hypertension systematic review and meta-analysis. *J Hypertens* 2016; 34: 600–
793 612.
- 794 [16] Xiong S, Berkhouse H, Schooler M, et al. Effectiveness of mHealth Interventions in Improving
795 Medication Adherence Among People with Hypertension: a Systematic Review. *Curr*
796 *Hypertens Rep* 2018; 20: 86.
- 797 [17] Hardeman W, Houghton J, Lane K, et al. A systematic review of just-in-time adaptive
798 interventions (JITAI) to promote physical activity. *Int J Behav Nutr Phys Act* 2019; 16: 31.
- 799 [18] Horne R, Cooper V, Wileman V, et al. Supporting Adherence to Medicines for Long-Term
800 Conditions. *Eur Psychol* 2019; 24: 82–96.
- 801 [19] Cornet VP, Holden RJ. Systematic review of smartphone-based passive sensing for health and
802 wellbeing. *J Biomed Inform* 2018; 77: 120–132.
- 803 [20] Pouls BPH, Vriezেকolk JE, Bekker CL, et al. Effect of Interactive eHealth Interventions on
804 Improving Medication Adherence in Adults With Long-Term Medication: Systematic Review. *J*
805 *Med Internet Res* 2021; 23: e18901.
- 806 [21] Lu X, Yang H, Xia X, et al. Interactive Mobile Health Intervention and Blood Pressure
807 Management in Adults. *Hypertension* 2019; 74: 697–704.
- 808 [22] Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ):
809 a 32-item checklist for interviews and focus groups. *Int J Qual Health Care* 2007; 19: 349–357.
- 810 [23] Cramer JA, Benedict Á, Muszbek N, et al. The significance of compliance and persistence in
811 the treatment of diabetes, hypertension and dyslipidaemia: a review. *Int J Clin Pract* 2008; 62:
812 76–87.
- 813 [24] Kassavou A, Sutton S. Reasons for non-adherence to cardiometabolic medications, and
814 acceptability of an interactive voice response intervention in patients with hypertension and
815 type 2 diabetes in primary care: a qualitative study. *BMJ Open* 2017; 7: e015597.
- 816 [25] Jamison J, Naughton F, Gilbert H, et al. Delivering Smoking Cessation Support by Mobile
817 Phone Text Message: What Information do Smokers Want? A Focus Group Study. *J Appl*
818 *Biobehav Res* 2013; 18: 1–23.
- 819 [26] Morton K, Sutton S, Hardeman W, et al. A Text-Messaging and Pedometer Program to
820 Promote Physical Activity in People at High Risk of Type 2 Diabetes: The Development of the
821 PROPELS Follow-On Support Program. *JMIR MHealth UHealth* 2015; 3: e105.

- 822 [27] Eborall H, Morton K. Use of Focus Groups in Developing Behavioural mHealth Interventions: A
823 Critical Review. In: Barbour RS, Morgan DL (eds) *A New Era in Focus Group Research:
824 Challenges, Innovation and Practice*. London: Palgrave Macmillan UK, pp. 109–127.
- 825 [28] Britten N. Qualitative Research: Qualitative interviews in medical research. *BMJ* 1995; 311:
826 251–253.
- 827 [29] Charmaz K. *Constructing Grounded Theory: A Practical Guide through Qualitative Analysis*.
828 SAGE, 2006.
- 829 [30] PAM - Programme on Adherence to Medication. *Primary Care Unit*,
830 [https://www.phpc.cam.ac.uk/pcu/research/research-groups/bsg/research-](https://www.phpc.cam.ac.uk/pcu/research/research-groups/bsg/research-themes/medication-adherence/pam-programme-on-adherence-to-medication/)
831 [themes/medication-adherence/pam-programme-on-adherence-to-medication/](https://www.phpc.cam.ac.uk/pcu/research/research-groups/bsg/research-themes/medication-adherence/pam-programme-on-adherence-to-medication/) (accessed 1
832 October 2020).
- 833 [31] Kassavou A, A'Court CE, Chauhan J, et al. Assessing the acceptability of a text messaging
834 service and smartphone app to support patient adherence to medications prescribed for high
835 blood pressure: a pilot study. *Pilot Feasibility Stud* 2020; 6: 134.
- 836 [32] National Institute for Health and Care Excellence. Evidence Standards Framework for Digital
837 Health Technologies., [https://www.nice.org.uk/Media/Default/About/what-we-do/our-](https://www.nice.org.uk/Media/Default/About/what-we-do/our-programmes/evidence-standards-framework/digital-evidence-standards-framework.pdf)
838 [programmes/evidence-standards-framework/digital-evidence-standards-framework.pdf](https://www.nice.org.uk/Media/Default/About/what-we-do/our-programmes/evidence-standards-framework/digital-evidence-standards-framework.pdf)
839 (2019, accessed 16 July 2020).
- 840 [33] Palacio A, Garay D, Langer B, et al. Motivational Interviewing Improves Medication
841 Adherence: a Systematic Review and Meta-analysis. *J Gen Intern Med* 2016; 31: 929–940.
- 842 [34] Aubeeluck E, Al-Arkee S, Finlay K, et al. The impact of pharmacy care and motivational
843 interviewing on improving medication adherence in patients with cardiovascular diseases: A
844 systematic review of randomised controlled trials. *Int J Clin Pract* 2021; 75: e14457.
- 845 [35] Zomahoun HTV, Guénette L, Grégoire J-P, et al. Effectiveness of motivational interviewing
846 interventions on medication adherence in adults with chronic diseases: a systematic review
847 and meta-analysis. *Int J Epidemiol* 2017; 46: 589–602.
- 848 [36] Leon N, Surender R, Bobrow K, et al. Improving treatment adherence for blood pressure
849 lowering via mobile phone SMS-messages in South Africa: a qualitative evaluation of the SMS-
850 text Adherence Support (StAR) trial. *BMC Fam Pract* 2015; 16: 80.
- 851 [37] Barber N. Should we consider non-compliance a medical error? *Qual Saf Health Care* 2002;
852 11: 81–84.
- 853 [38] Horne R, Chapman SCE, Parham R, et al. Understanding Patients' Adherence-Related Beliefs
854 about Medicines Prescribed for Long-Term Conditions: A Meta-Analytic Review of the
855 Necessity-Concerns Framework. *PLOS ONE* 2013; 8: e80633.
- 856 [39] Nelson LA, Mulvaney SA, Johnson KB, et al. mHealth Intervention Elements and User
857 Characteristics Determine Utility: A Mixed-Methods Analysis. *Diabetes Technol Ther* 2017; 19:
858 9–17.
- 859 [40] Hirschey J, Bane S, Mansour M, et al. Evaluating the Usability and Usefulness of a Mobile App
860 for Atrial Fibrillation Using Qualitative Methods: Exploratory Pilot Study. *JMIR Hum Factors*
861 2018; 5: e13.

- 862 [41] Grindrod KA, Li M, Gates A. Evaluating User Perceptions of Mobile Medication Management
863 Applications With Older Adults: A Usability Study. *JMIR MHealth UHealth*; 2. Epub ahead of
864 print 14 March 2014. DOI: 10.2196/mhealth.3048.
- 865 [42] Nelson LA, Bethune MC, Lagotte AE, et al. The Usability of Diabetes MAP: A Web-delivered
866 Intervention for Improving Medication Adherence. *JMIR Hum Factors* 2016; 3: e13.
- 867 [43] Lucivero F, Jongsma KR. A mobile revolution for healthcare? Setting the agenda for bioethics.
868 *J Med Ethics* 2018; 44: 685–689.
- 869 [44] Lupton D. The digitally engaged patient: Self-monitoring and self-care in the digital health era.
870 *Soc Theory Health* 2013; 11: 256–270.
- 871 [45] Ramanathan N, Swendeman D, Comulada WS, et al. Identifying preferences for mobile health
872 applications for self-monitoring and self-management: focus group findings from HIV-positive
873 persons and young mothers. *Int J Med Inf* 2013; 82: e38-46.
- 874 [46] Dennison L, Morrison L, Conway G, et al. Opportunities and Challenges for Smartphone
875 Applications in Supporting Health Behavior Change: Qualitative Study. *J Med Internet Res*
876 2013; 15: e2583.
- 877 [47] Naughton F, Hopewell S, Lathia N, et al. A Context-Sensing Mobile Phone App (Q Sense) for
878 Smoking Cessation: A Mixed-Methods Study. *JMIR MHealth UHealth* 2016; 4: e106.
- 879 [48] Boonstra TW, Nicholas J, Wong QJ, et al. Using Mobile Phone Sensor Technology for Mental
880 Health Research: Integrated Analysis to Identify Hidden Challenges and Potential Solutions. *J*
881 *Med Internet Res* 2018; 20: e10131.
- 882 [49] Szinay D, Jones A, Chadborn T, et al. Influences on the Uptake of and Engagement With
883 Health and Well-Being Smartphone Apps: Systematic Review. *J Med Internet Res* 2020; 22:
884 e17572.
- 885 [50] Fortuna RJ, Nagel AK, Rocco TA, et al. Patient Experience With Care and Its Association With
886 Adherence to Hypertension Medications. *Am J Hypertens* 2018; 31: 340–345.
- 887 [51] Haskard Zolnieriek KB, DiMatteo MR. Physician Communication and Patient Adherence to
888 Treatment: A Meta-Analysis. *Med Care* 2009; 47: 826–834.
- 889 [52] Harmon G, Lefante J, Krousel-Wood M. Overcoming barriers: the role of providers in
890 improving patient adherence to antihypertensive medications. *Curr Opin Cardiol* 2006; 21:
891 310–315.
- 892 [53] 1 Recommendations | Behaviour change: individual approaches | Guidance | NICE,
893 <https://www.nice.org.uk/guidance/ph49/chapter/1-Recommendations> (accessed 4 May
894 2021).
- 895 [54] Carson KV, Verbiest ME, Crone MR, et al. Training health professionals in smoking cessation.
896 *Cochrane Database Syst Rev*. Epub ahead of print 2012. DOI:
897 10.1002/14651858.CD000214.pub2.

898